Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

TThis is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


For brand teams, launch year has become a nightmare of denials, delays and deep discounts.

For the one in 10 drugs tested in clinical trials that wins FDA approval, payer coverage is becoming an exception to the rule. Therapeutic drug purchases in the US are mediated largely by large national insurance companies that purchase drugs on behalf of patients and negotiate net price with drug makers as well as rationalize care. The co-mingled roles of large insurance companies in negotiating price on one hand and choosing which agents rationally patients should be allowed to use on the other hand set up an unfortunate scenario at launch. Uncover the strategies and trends:

  • The new therapeutics from 2018 compared with most current approved drug lists of large national payers
  • The types of new products making it to the published formularies
  • Access scenarios for commercial versus Medicare
alt text

Complete the form to download the whitepaper.

By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio
By ticking this box, you agree to receive emails such as promotional offers from other members of the Informa group and selected 3rd party companies

By completing this form you agree to receive communications from Syneos Health. Syneos Health values your privacy. Click here to view the Syneos Health privacy policy.